메뉴 건너뛰기
European Journal of Cancer
Volumn 49, Issue 9, 2013, Pages 2269-2270
The PARAMOUNT study and the re-challenge chemotherapy issue in advanced non-small cell lung cancer
Author keywords

[No Author keywords available]
Indexed keywords

CISPLATIN; GEMCITABINE; PEMETREXED; THYMIDYLATE SYNTHASE;
EID: 84877710748     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.02.038     Document Type: Letter
Times cited : (1)
References (6)
  • 1
    • 70249130544 scopus 로고    scopus 로고
    • Duration of chemotherapy for advanced non-small-cell lung cancer: A systematic review and meta-analysis of randomized trials
    • Y.Y. Soon, M.R. Stockler, and L.M. Askie Duration of chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized trials J Clin Oncol 27 2009 3277 3283
    • (2009) J Clin Oncol , vol.27 , pp. 3277-3283
    • Soon, Y.Y.1    Stockler, M.R.2    Askie, L.M.3
  • 2
    • 49049089802 scopus 로고    scopus 로고
    • Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer
    • G.V. Scagliotti, P. Parikh, and J. von Pawel Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer J Clin Oncol 26 2008 3543 3551
    • (2008) J Clin Oncol , vol.26 , pp. 3543-3551
    • Scagliotti, G.V.1    Parikh, P.2    Von Pawel, J.3
  • 3
    • 0036498921 scopus 로고    scopus 로고
    • Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens
    • M.G. Cantù, A. Buda, and G. Parma Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens J Clin Oncol 20 2002 1232 1237
    • (2002) J Clin Oncol , vol.20 , pp. 1232-1237
    • Cantù, M.G.1    Buda, A.2    Parma, G.3
  • 4
    • 77957550828 scopus 로고    scopus 로고
    • Re-challenging with anthracyclines and taxanes in metastatic breast cancer
    • C. Palmieri, J. Krell, and C.R. James Re-challenging with anthracyclines and taxanes in metastatic breast cancer Nat Rev Clin Oncol 7 2010 561 574
    • (2010) Nat Rev Clin Oncol , vol.7 , pp. 561-574
    • Palmieri, C.1    Krell, J.2    James, C.R.3
  • 5
    • 79952194560 scopus 로고    scopus 로고
    • Pemetrexed re-challenge in pleural malignant mesothelioma: An option for a subset of patients initially treated with pemetrexed-platinum doublets in the first-line setting?
    • G. Zalcman, E. Bergot, and E. Lechapt Pemetrexed re-challenge in pleural malignant mesothelioma: an option for a subset of patients initially treated with pemetrexed-platinum doublets in the first-line setting? Lung Cancer 72 2011 1 2
    • (2011) Lung Cancer , vol.72 , pp. 1-2
    • Zalcman, G.1    Bergot, E.2    Lechapt, E.3
  • 6
    • 0023851771 scopus 로고
    • First line chemotherapy rechallenge after relapse in small cell lung cancer
    • M. Vincent, B. Evans, and I. Smith First line chemotherapy rechallenge after relapse in small cell lung cancer Cancer Chemother Pharmacol 21 1988 45 48
    • (1988) Cancer Chemother Pharmacol , vol.21 , pp. 45-48
    • Vincent, M.1    Evans, B.2    Smith, I.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.